Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$0.78
-1.3%		$0.93
$0.46
▼
$1.69
$8.67M0.2318,541 shs25,319 shs
BioVie Inc. stock logo
BIVI
BioVie
$1.84
+13.3%		$1.71
$1.06
▼
$6.01
$13.84M0.6124,646 shs382,407 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.18
+0.2%		$0.21
$0.16
▼
$3.99
$2.65M-0.141.65 million shs163,310 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.30
+20.8%		$0.43
$0.20
▼
$5.14
$12.15M0.412.17 million shs114.88 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-12.22%-15.42%-45.14%+14.71%+17.91%
BioVie Inc. stock logo
BIVI
BioVie
+6.58%+18.25%-16.92%-1.82%-73.13%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-0.11%+4.47%-15.27%-46.25%-94.78%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
+1.66%+6.43%-1.57%-59.18%-91.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$0.78
-1.3%		$0.93
$0.46
▼
$1.69
$8.67M0.2318,541 shs25,319 shs
BioVie Inc. stock logo
BIVI
BioVie
$1.84
+13.3%		$1.71
$1.06
▼
$6.01
$13.84M0.6124,646 shs382,407 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.18
+0.2%		$0.21
$0.16
▼
$3.99
$2.65M-0.141.65 million shs163,310 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$0.30
+20.8%		$0.43
$0.20
▼
$5.14
$12.15M0.412.17 million shs114.88 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-12.22%-15.42%-45.14%+14.71%+17.91%
BioVie Inc. stock logo
BIVI
BioVie
+6.58%+18.25%-16.92%-1.82%-73.13%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-0.11%+4.47%-15.27%-46.25%-94.78%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
+1.66%+6.43%-1.57%-59.18%-91.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00
N/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
2.00
Hold$6.253,455.18% Upside
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.80
Reduce$0.95220.95% Upside

Current Analyst Ratings Breakdown

Latest SNYR, BIVI, VTGN, and BCLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/29/2026
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/12/2026
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/11/2026
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/3/2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$9.93 per shareN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$30.38M0.09N/AN/A($2.06) per share-0.09
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$1.27M9.56N/AN/A$0.90 per share0.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$1.64N/AN/AN/AN/AN/A-519.50%8/17/2026 (Estimated)
BioVie Inc. stock logo
BIVI
BioVie
-$17.54M-$2.45N/AN/AN/AN/A-101.15%-90.18%8/24/2026 (Estimated)
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-$12.34M-$1.40N/A1.17N/A-60.02%N/A-30.30%N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$69.68M-$1.83N/AN/AN/A-5,487.01%-133.02%-105.79%8/6/2026 (Estimated)

Latest SNYR, BIVI, VTGN, and BCLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/24/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52N/AN/AN/AN/AN/A
8/17/2026Q2 2026
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.29N/AN/AN/AN/AN/A
8/6/2026Q1 2027
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.3650N/AN/AN/A$0.50 millionN/A
6/15/2026Q4 2026
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.3367-$0.37-$0.0333-$0.37$0.40 million$0.47 million
5/14/2026Q1 2026
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.03-$0.23-$0.26-$0.23N/A$5.49 million
5/11/2026Q3 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.73-$0.70+$0.03-$0.70N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.96
9.96
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A
0.93
0.43
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
3.67
3.67

Institutional Ownership

CompanyInstitutional Ownership
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
11.15%
BioVie Inc. stock logo
BIVI
BioVie
0.90%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
32.90%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
2.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4011.12 million8.74 millionOptionable
BioVie Inc. stock logo
BIVI
BioVie
107.54 million7.47 millionNo Data
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
4015.08 million10.12 millionN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4041.03 million39.86 millionOptionable

Recent News About These Companies

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Average Price Target from Brokerages
August 4 at 3:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30939709
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336795/0/en/vistagen-appoints-douglas-j-williamson-to-its-board-of-directors.html
Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
July 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VTGN/pressreleases/3154507/stifel-nicolaus-remains-a-hold-on-vistagen-therapeutics-vtgn/
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
July 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-vistagen-therapeutics-inc-vtgn-stock-facing-new-challenges-after-palisade-4-clinical-trial-results-1801646/
VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst
July 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VTGN/pressreleases/3092835/vistagen-therapeutics-vtgn-receives-a-rating-update-from-a-top-analyst/
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918929-vistagen-therapeutics-inc-vtgn-discusses-palisademinus-4-phase-iii-results-and-post-hoc
Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet
June 30, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/vistagens-anxiety-disorder-drug-misses-main-goal-late-stage-trial-shares-plummet-2026-06-30/
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vistagen-therapeutics-2026-workforce-cuts-raise-execution-risks-and-threaten-long-term-growth?utm_source=marketbeat.com&utm_medium=referral
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
June 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260615159406/en/Vistagen-Reports-Fiscal-Year-2026-Financial-Results-and-Provides-Corporate-Update/
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260609888048/en/Vistagen-Achieves-Minimum-ICH-Safety-Exposure-Recommendations-Across-Clinical-Program-for-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder/
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
June 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519798012/en/vistagen-appoints-angel-s.-angelov-md-mba-as-chief-medical-officer/
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
May 19, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-vistagen-therapeutics-inc-vtgn-a-breakout-anxiety-drug-stock-after-new-phase-3-extension-results-1764536/
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512521110/en/Vistagen-Announces-Preliminary-Positive-Data-in-Ongoing-Open-Label-Extension-Portion-of-PALISADE-3-Phase-3-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder/
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
May 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260508181101/en/Vistagen-Announces-Completion-of-Last-Patient-Visit-in-PALISADE-4-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-Acute-Treatment-of-Social-Anxiety-Disorder/
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3284191/0/en/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm.html
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/vistagen-therapeutics-inc-nasdaq-vtgn-investor-alert-schubert-jonckheer-investigating-possible-false-claims-regarding-drug-candidate-following-80-stock-drop-302755351.html
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
April 22, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260422186960/en/vistagen-receives-fda-%e2%80%9cstudy-may-proceed%e2%80%9d-letter-under-its-refisolone-ind-application-enabling-further-phase-2-clinical-development-for-the-treatment-of-vasomotor-symptoms-hot-flashes-due-to-menopause/
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
April 20, 2026  |  newsfilecorp.comN
VistaGen Faces Nasdaq Audit Committee Compliance Setback
April 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/vistagen-faces-nasdaq-audit-committee-compliance-setback?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.78 -0.01 (-1.27%)
As of 03:49 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BioVie stock logo

BioVie NASDAQ:BIVI

$1.84 +0.22 (+13.33%)
Closing price 03:58 PM Eastern
Extended Trading
$1.83 -0.01 (-0.33%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Synergy CHC stock logo

Synergy CHC NASDAQ:SNYR

$0.18 +0.00 (+0.23%)
As of 03:57 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$0.30 +0.05 (+20.82%)
Closing price 03:59 PM Eastern
Extended Trading
$0.30 +0.01 (+2.36%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas